One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
The investment will increase SpeeDx internal capacity to scale up manufacturing
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients
The company does not expect the outcome of this inspection to impact its plans
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
The company will leverage existing hospital and clinic partners’ infrastructure to build specialised `Experience Centres’ and facilitate a seamless, end-to-end secondary care surgery delivery. It will also offer healthcare financing
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
The company is the Clinical Research Organisation of Caplin Point Laboratories
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Subscribe To Our Newsletter & Stay Updated
